The Swedish BioFINDER Study

7/🧵 These results suggest that hemispheric difference in Aβ deposition, rather than reduction in connectivity, is associated with asymmetric tau accumulation, highlighting regional vulnerability as a crucial factor in determining the distribution of AD pathology.

Big thanks to all co-authors and collaborators: @RikOssenkoppele @ErikRubenSmith @LECollij @aitchbi @jorittmo @karlssonlinda1 @DaniellevWe @JakeVogel @EStomrud @SebastianPalmqv @NiklasMattsson4 @NicolaSpotorno @OskarHansson9 + those not on X

4⃣In summary, we have developed a biomarker-based staging model using plasma tau biomarkers and validated in TRIAD. We believe these findings will enhance the application of blood tau biomarkers, improving patient management in both clinical trials and routine clinical practice.

Thanks to all coauthors: @JosephTherr , @NicholasAshton, @andrealessa, @NiklasMattsson4, @SebastianPalmqv, @EStomrud, @pedrorosaneto, and @OskarHansson9
And those not on X.

6/🧵Taken together, we present an accurate two-step approach for predicting LBP in the brain using a smell test followed by CSF SAA testing in smell-test positive individuals. This could minimize costs, reduce patient burden, and improve the known underdiagnosis of DLB and PD.

A huge thanks to all authors and collaborators who made this work possible! @OskarHansson9 @LECollij @_JakeVogel_ @SebastianPalmqv @FBarkhof @RikOssenkoppele and all not on X.